Stevanato Group S.p.A.

Good afternoon. This is the Coruscant Conference Operator. Welcome and thank you for joining the Stevanato Group Third Quarter 2023 Financial Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Ms. Lisa Miles, Senior Vice President, Investor Relations. Please go ahead, Madam.

Good morning, and thank you for joining us. You can find a presentation to accompany today's results on the Investor Relations page of our website, which can be found under the Financial Results tab. As a reminder, some statements being made today will be forward-looking in nature and are only predictions. Actual events and results may differ materially as a result of risks we face, including those discussed in item 3D entitled Risk Factors in the company's most recent annual report on Form 20F filed with the SEC. Please take a moment to read our Safe Harbor Statement, including in the front of today's presentation. We encourage you to review the information contained in our most recent SEC filings, including our latest Form 20F filed on March 2, 2023. The company does not assume any obligation to revise or update these forward-looking statements to reflect subsequent events or circumstances except as required by law. Today's presentation may contain non-GAAP financial information. Management uses this information in its internal analyses of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period-to-period comparisons. For reconciliation of the non-GAAP measures, please see the company's most recent earnings press release. I will now hand the call over to Franco Stevanotto for opening remarks.

Thank you, Lisa. This morning, we reported our third quarter results with double-digit revenue growth and an adjusted EBITDA margin of 27.5%, in line with our near-term financial targets. While third quarter revenue in the engineering segment fell short of our expectations, largely due to timing of revenue, we remain confident that we can achieve our full year guidance. As we alighted at our capital markets day, the fundamentals of our business remain strong. For the last 50 years, our focus has been on delivering the highest quality products to pharmaceutical customers worldwide. Our unique value proposition of integrated end-to-end solutions has helped us become a living partner of choice. We support customers through the entire drug lifecycle, from early stage drug development through commercializations. Our differentiated products embed science and technology to meet the most stringent standards that customers demand. We are currently benefiting from macro trends such as edgy populations, the rise in biologics and biosimilar, and the shift towards self-administration of medicine. We operate in growing end markets, particularly biologics, where we have built a leadership position in treatment areas such as JP1, monoclonal antibodies, and mRNA applications. As previously disclosed, of 2022 FDA approvals, we are present in three out of four of the potential blockbusters, all of which are biologics. Biologics, which are mostly administered through injections, are delivering breakthrough results in patient care, but they tend to be costly and more challenging to manufacture due to their sensitive nature. These factors are driving demand for high-performing drug containment to ensure the integrity and stability of treatments delivered to patients. Moreover, the global pipeline of drugs in development is at record levels with more than 60% in injectable formats. In summary, we believe that these positive trends position us well to capitalize on the many favorable secular tailwinds. We are focused on executing against our strategic priorities to deliver sustainable organic growth and build shareholder value. Thank you. I will now hand the call over to Marco.